Clinical Trials Using Radium Ra 223 Dichloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Radium Ra 223 Dichloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-11 of 11
  • Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase III trial studies docetaxel and radium Ra 223 dichloride to see how well it works compared with docetaxel alone in treating patients with prostate cancer that has spread to other places in the body, despite the surgical removal of the testes or medical intervention to block androgen production. Drugs used in chemotherapy, such as docetaxel and radium Ra 223 dichloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known whether docetaxel with or without radium Ra 223 dichloride works better at treating metastatic castration-resistant prostate cancer.
    Location: 24 locations

  • Olaparib and Radium Ra 223 Dichloride in Treating Men with Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone

    This phase I / II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may work better at treating castration-resistant prostate cancer.
    Location: 10 locations

  • Radium Ra 223 Dichloride and Niraparib in Treating Patients with Castration-Resistant Prostate Cancer Metastatic to the Bone

    This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating patients with castration-resistant prostate cancer that has spread from the primary site to the bone. Radium Ra 223 dichloride, acts like calcium to target cancer in the bones and may deliver radiation directly to the bone tumors, limiting damage to the surrounding normal tissue. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radium Ra 223 dichloride and niraparib may work better in treating patients with castration-resistant prostate cancer metastatic to the bone.
    Location: 6 locations

  • Enzalutamide with or without Radium Ra 223 Dichloride in Patients with Metastatic, Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well enzalutamide with or without radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Enzalutamide is an androgen receptor inhibitor that may slow down the growth of prostate cancer by blocking the action of the male hormone testosterone and other male hormones called androgens. Radiation therapy uses high energy alpha particles to kill tumor cells and shrink tumors. Enzalutamide with or without radium Ra 223 dichloride may work better in treating patients with castration-resistant prostate cancer.
    Location: 3 locations

  • Pembrolizumab and Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well pembrolizumab and radium Ra 223 dichloride work in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Pembrolizumab works to block the PD-1 pathway, which plays an important role in lessening the activity of one’s immune system to fight cancer. Pembrolizumab is therefore referred to as a PD-1 inhibitor, and acts by stimulating the patient’s T cells, which are important immune cells, to attack tumors and treat cancer. Radium-223 targets cancer that exists in the bone directly. Radium-223 binds to minerals in the bone to deliver radiation directly to the tumor that has spread to the bones while limiting damage to the surrounding body tissues. Giving pembrolizumab and radium Ra 223 dichloride together may work better in treating patients with castration-resistant prostate cancer.
    Location: 3 locations

  • Rapid Cycle Combination Therapy in Treating Patients with Metastatic Castrate-Resistant Prostate Cancer

    This phase II trial studies how well rapid cycle combination therapy works in treating patients with prostate cancer that has not responded to surgery or hormone therapy and has spread to other places in the body. Androgen can cause the growth of tumor cells. Antihormone therapy, such as abiraterone acetate and enzalutamide, may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as radium Ra 223 dichloride, cabazitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Switching between different combinations of androgen deprivation therapy and chemotherapy after a short time may prevent drug resistance and help achieve better long-term control of prostate cancer.
    Location: 2 locations

  • SABR with or without Radium-223 for the Treatment of Metastatic Prostate Cancer

    This phase II trial studies how well stereotactic ablative radiation therapy (SABR) with or without radium-223 works in treating patients with prostate cancer that has spread to the bone (bone metastases) or soft tissue (soft tissue metastases). SABR uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Radioactive drugs, such as radium-223, may carry radiation directly to tumor cells and not harm normal cells. Giving SABR together with radium-223 may work better in treating patients with prostate cancer compared to SABR alone.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Prostate Cancer

    This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body. Radium Ra 223 dichloride contains a radioactive substance that collects in the bone and gives off radiation that may kill cancer cells. Hormone therapy using leuprolide acetate or goserelin acetate may fight prostate cancer by lowering the amount of testosterone the body makes. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving radium Ra 223 dichloride, hormone therapy and stereotactic body radiation may work better at treating prostate cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Radium Ra 223 Dichloride and External Beam Radiation Therapy in Treating Patients with Prostate Cancer Metastatic in the Bone

    This phase II trial studies how well radium Ra 223 dichloride and external beam radiation therapy work in treating patients with prostate cancer that has spread to the bone. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving radium Ra 223 dichloride and external beam radiation therapy together may work better in treating patients with prostate cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well radium Ra 223 dichloride works in treating patients with prostate cancer that has spread to the bone (metastatic) and is resistant to hormone therapy. Radium Ra 223 dichloride is a radioactive drug that may kill tumor cells by damaging the tumor cells deoxyribonucleic acid (DNA) with limited toxicity to nearby healthy bone tissue. Studying samples of blood in the laboratory from patients receiving radium Ra 223 dichloride may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors understand how well patients respond to treatment.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Carbon-11 Acetate PET / CT Imaging in Evaluating Response to Radium Ra 223 Dichloride Therapy in Patients with Hormone-Resistant Metastatic Prostate Cancer

    This pilot clinical trial studies carbon-11 acetate positron emission tomography / computed tomography (PET / CT) in evaluating response to radium Ra 223 dichloride therapy in patients with prostate cancer that has not responded to previous treatment with hormones and that has spread to the bones. Carbon-11 acetate is a specialized radioactive drug that is used to allow imaging of tissue using a PET / CT scanner which is specialized to detect a small radioactive signal. Carbon-11 acetate is used to evaluate cell growth and how fast cells replicate. The amount of carbon-11 acetate that is taken up by cancer cells before and after radium Ra 223 therapy may help to understand whether patients with hormone-resistant metastatic prostate cancer are responding to treatment.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania